[PDF][PDF] EGFR-TKI 致肝损伤的研究进展
田宏① - 中国医学创新, 2015 - zgyxcx.com
… gefitinib and erlotinib,we found frequencies of high-grade (grade 3 or above)hepatic adverse
events of EGFR-TKIs varies from 1… Erlotinib in advanced non-small cell lung cancer efficacy …
events of EGFR-TKIs varies from 1… Erlotinib in advanced non-small cell lung cancer efficacy …
[HTML][HTML] 吉非替尼对比培美曲塞二线治疗晚期非鳞型非小细胞肺癌的随机对照临床研究
戴宏宇， 徐玲， 夏春伟， 陈文萍 - Chinese Journal of Lung Cancer, 2013 - ncbi.nlm.nih.gov
… (NSCLC), although studies comparing the two drugs are … versus gefitinib versus erlotinib
in previously treated patients … Correlation analysis of gender and efficacy of Gefitinib in …
in previously treated patients … Correlation analysis of gender and efficacy of Gefitinib in …
[HTML][HTML] 培美曲赛单药与培美曲赛联合奥沙利铂用于Ⅳ 期肺腺癌挽救性治疗的比较
刘友如， 江银铃， 高志强， 王向迎， 韩宝惠… - Chinese Journal of …, 2011 - ncbi.nlm.nih.gov
… The aim of this study is to compare the efficacies and safeties of pemetrexed alone with …
inhibitors, EGFR-TKIs）吉非替尼（gefitinib）和厄洛替尼（erlotinib）已成为标准治疗之一，尤其对肺腺…
inhibitors, EGFR-TKIs）吉非替尼（gefitinib）和厄洛替尼（erlotinib）已成为标准治疗之一，尤其对肺腺…
[PDF][PDF] 甲氧氯普胺和马来酸氯苯那敏联合预防荧光素钠的不良反应
刘桦， 郝晓琳， 戴维智， 徐彦玲， 金红霞， 付晓璐 - 临床药物治疗杂志, 2013 - lcywzlzz.com
… [Abstract] Objective: To evaluate the safety and effectiveness … ; incidents of severe adverse
events was 1.79%(group1 0.27… ), there were significant difference between the two groups (P<…
events was 1.79%(group1 0.27… ), there were significant difference between the two groups (P<…
香菇多糖注射液对直肠癌根治术后患者纤维蛋白水平及免疫功能的影响.
徐文珠， 李萍， 崔静， 韩笑… - Progress in Modern …, 2016 - search.ebscohost.com
… The incidence of adverse reaction during chemotherapy … of observation group had no
difference compared with those before … efficacy of HDAC inhibitors SAHA and LBH589 in patient-…
difference compared with those before … efficacy of HDAC inhibitors SAHA and LBH589 in patient-…
[PDF][PDF] 大剂量利巴韦林联合干扰素治疗快速病毒学应答不佳慢性丙型肝炎的疗效评价
刘俊英 - 临床药物治疗杂志, 2013 - lcywzlzz.com
… [Abstract] Objective: To evaluate the efficacy of high-dose ribavirin plus interferon for poor …
SVR among the three groups were compared . Results: In group A, there were 26 patients …
SVR among the three groups were compared . Results: In group A, there were 26 patients …
[PDF][PDF] 吉非替尼治疗老年晚期非小细胞肺癌的疗效观察
李苏霞， 杨晓蕾， 陈素秀， 刘洁凡… - … 临床药理学与治疗学, 2013 - manu41.magtech.com.cn
… Efficacy and safety of gefitinib treated elded-patients with … but had no significant difference(P>
0.05).CONCLUSION:The … was better,and incidence of adverse reaction was lower,that can …
0.05).CONCLUSION:The … was better,and incidence of adverse reaction was lower,that can …
[PDF][PDF] 第一代EGFR-TKI 治疗晚期肺腺癌耐药后联合阿帕替尼继续治疗的效果
冯宇， 朱豪华， 胡兴胜， 刘雨桃， 邢镨元， 王宏羽… - 临床药物治疗 …, 2020 - lcywzlzz.com
… no significant difference between median PFS2 and patients … -TKI with apatinib is efficacious
in the treatment of patients with … (common terminology criteria for adverse event, CTCAE)4. 0…
in the treatment of patients with … (common terminology criteria for adverse event, CTCAE)4. 0…
EGFR 靶向治疗的现状机遇和挑战
高琳， 虞永峰， 陆舜 - 中国肿瘤临床, 2021 - cjco.cn
… 最常见的不良反应(adverse events,AEs)是皮 肤和胃肠道反应.第二代药物的AEs 较第一,三代…
Efficacy and safety of gefitinib as thirdline treatment in NSCLC patients with activating EGFR …
Efficacy and safety of gefitinib as thirdline treatment in NSCLC patients with activating EGFR …